Press release
Amyotrophic Lateral Sclerosis Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024
Explore our latest breakthroughs in Amyotrophic Lateral Sclerosis research. Learn more about our innovative pipeline today! @ Amyotrophic Lateral Sclerosis Pipeline Outlook [https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Amyotrophic Lateral Sclerosis Pipeline Report
* In September 2024:- Ionis Pharmaceuticals Inc.- A Phase 1-3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION363 in Amyotrophic Lateral Sclerosis Patients With Fused in Sarcoma Mutations (FUS-ALS). The primary purpose of this study is to evaluate the efficacy of ION363 on clinical function and survival in carriers of fused in sarcoma mutations with amyotrophic lateral sclerosis (FUS-ALS).
* In September 2024:- UniQure Biopharma B.V.- A Phase 1/2, Multicenter, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Exploratory Efficacy of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants with SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS). This is the study of AMT-162 in Participants with SOD1-ALS and is designed to evaluate the safety, tolerability, and exploratory efficacy of intrathecally administered gene therapy AMT-162. AMT-162-001 is a Phase 1/2, multi-center, single ascending dose study.
* In September 2024:- Rapa Therapeutics LLC- RAPA-501-ALS is an Intermediate-Size Expanded Access Trial of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS). This is an open-label, non-randomized, multi-center intermediate size expanded access clinical trial of single-agent RAPA-501 cells in patients with high-risk ALS who are not eligible for other ALS clinical trials.
* In September 2024:- Revalesio Corporation- Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis. The purpose of this study is to determine whether nebulized RNS60 is effective in the treatment of amyotrophic lateral sclerosis (ALS).
* In September 2024:- Everfront Biotech Co., Ltd.- The study drugs (including placebo) will be administered at the study site by following the investigator's instructions to either perform blood sampling for pharmacokinetic evaluation or maximize the treatment compliance.
* DelveInsight's Amyotrophic Lateral Sclerosis pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Amyotrophic Lateral Sclerosis treatment.
* The leading Amyotrophic Lateral Sclerosis Companies such as Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith, Verge Genomics, UCB , and others.
* Promising Amyotrophic Lateral Sclerosis Therapies such as Dazucorilant 300 mg, AP-101, Fasudil (WP-0512), ION363 , and others.
Stay informed about the cutting-edge advancements in Amyotrophic Lateral Sclerosis treatments. Download for updates and be a part of the revolution in cancer care @ Amyotrophic Lateral Sclerosis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Amyotrophic Lateral Sclerosis Emerging Drugs Profile
* MN-166: MediciNova
MN-166 is a first-in-class, orally bioavailable, small molecule glial attenuator that suppresses pro-inflammatory cytokines IL-1Ss, TNF-a, and IL-6, and may upregulate the anti-inflammatory cytokine IL-10. It has additionally been shown to be a toll-like receptor 4 (TLR4) functional antagonist that may contribute to its attenuation of neuroinflammation. The drug is currently being evaluated under Phase II/III clinical trial for the treatment of ALS.
* RNS60: Revalesio
RNS60 is being developed to provide disease modifying and potentially restorative treatments for neurological diseases. The drug activates intracellular signaling pathways to increase mitochondrial biogenesis and function and reduce inflammation. RNS60 safely protects neurons and oligodendrocytes and modulates the activity of immune cells to restore homeostasis. RNS60 has been granted Orphan Drug and Fast Track designations for ALS from the US Food and Drug Administration. The drug is currently being evaluated under Phase II clinical trial for the treatment of ALS.
* VM202: Helixmith
VM202 is an innovative gene therapy drug that provides fundamental treatment through tissue regeneration. The drug is injected along the peripheral nerves and their branches, the internal production of HGF may protect nerves and promote the growth of neurons while also ameliorating atrophic conditions. The US FDA granted orphan drug and fast track designation to VM202. The drug is currently being evaluated under Phase II clinical trial for the treatment of ALS.
* QRL-201: QurAlis Corporation
QRL-201 is a first-in-class therapeutic product candidate aiming to restore STMN2 expression in ALS patients. STMN2 is a well-validated protein important for neural repair and axonal stability, the expression of which is significantly decreased in nearly all ALS patients. QRL-201 rescues STMN2 loss of function in QurAlis ALS patient-derived motor neuron disease models in the presence of TDP-43 pathology. The drug is currently being evaluated under Phase I clinical trial for the Amyotrophic Lateral Sclerosis treatment.
Learn more about Amyotrophic Lateral Sclerosis Drugs opportunities in our groundbreaking Amyotrophic Lateral Sclerosis Research and development projects @ Amyotrophic Lateral Sclerosis Unmet Needs [https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Amyotrophic Lateral Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Intravenous
* Subcutaneous
* Oral
* Intramuscular
Amyotrophic Lateral Sclerosis Products have been categorized under various Molecule types such as
* Monoclonal antibody
* Small molecule
* Peptide
Discover the latest advancements in Amyotrophic Lateral Sclerosis treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Amyotrophic Lateral Sclerosis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Amyotrophic Lateral Sclerosis Pipeline Report
* Coverage- Global
* Amyotrophic Lateral Sclerosis Companies- Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith, Verge Genomics, UCB, and others.
* Amyotrophic Lateral Sclerosis Therapies- Dazucorilant 300 mg, AP-101, Fasudil (WP-0512), ION363, and others.
* Amyotrophic Lateral Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Amyotrophic Lateral Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Amyotrophic Lateral Sclerosis Pipeline on our website @ Amyotrophic Lateral Sclerosis Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/amyotrophic-lateral-sclerosis-als-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Amyotrophic Lateral Sclerosis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Amyotrophic Lateral Sclerosis- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II/III)
* MN-166: MediciNova
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* QRL-201: QurAlis Corporation
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Amyotrophic Lateral Sclerosis Key Companies
* Amyotrophic Lateral Sclerosis Key Products
* Amyotrophic Lateral Sclerosis- Unmet Needs
* Amyotrophic Lateral Sclerosis- Market Drivers and Barriers
* Amyotrophic Lateral Sclerosis- Future Perspectives and Conclusion
* Amyotrophic Lateral Sclerosis Analyst Views
* Amyotrophic Lateral Sclerosis Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=amyotrophic-lateral-sclerosis-pipeline-insights-treatment-drugs-clinical-trials-and-companies-2024]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Amyotrophic Lateral Sclerosis Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024 here
News-ID: 3671265 • Views: …
More Releases from ABNewswire
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold.
Responding to a Growing Need for Water Damage Restoration
Property owners across Minnesota are increasingly seeking…
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents.
Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,…
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces.
In…
![Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices](https://cdn.open-pr.com/9/1/914818326_g.jpg)
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection.
Market Overview: Understanding Tampa Bay Remodeling Investment Trends
Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.…
More Releases for Late
Transformative Trends Impacting the Late Stage Chronic Kidney Disease Drugs Mark …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Late Stage Chronic Kidney Disease Drugs Market Size By 2025?
In recent times, the market size for drugs treating late-stage chronic kidney disease has experienced a swift growth. It is projected to rise from $7.08 billion in 2024 to $7.86 billion in 2025, indicating a…
Late Night Revelry Awaits at The Winslow Lounge - NYC's Premier Late-Night Desti …
Image: https://www.getnews.info/wp-content/uploads/2024/06/1713864312.jpeg
New York, NY - The Winslow Lounge, located in the heart of the East Village, has quickly become the premier late-night destination [https://thewinslownyc.com/late-night-bar-nyc/] in New York City. With its vibrant atmosphere, exciting entertainment options, delicious food and drinks, and lively events, The Winslow offers an unforgettable nightlife experience.
"We wanted to create a place in NYC where people could truly let loose and have an amazing time," said Mark Tafoya,…
Desperate Puppy Seeks Rescue Before It’s Too Late!
FOR IMMEDIATE RELEASE
Tucson AZ, December 14th, 2021
The StarBarksCoffee.com rescue team was recently assaulted and threatened with being shot for assisting an abused, entangled puppy.
This Video of a neglected puppy desperately seeking rescue from a mentally unstable and violently aggressive owner was taken recently at an RV park in Texas during our annual "Journey Across America" in support of Animal Welfare.
We've contacted Texas authorities, but the Sheriff’s Department informed us the…
Transform your Traditional Businesses Before Its Too Late
Mob Inspire, an app development company has disrupted many industries by providing innovative software solutions to traditional businesses. We understand the rapidly changing tech environment and therefore equipt ourselves with those skills and tech tools which enable us to deal with challenging situations efficiently.
Mob Inspire takes the leverage of the latest tech trends like Blockchain, IoT and Cloud to deliver high-end products to its clients. The popularity…
Late-Night Treats for Late-Night Peeps
WHAT: La Motta’s, the neighborhood favorite in Boston’s SoWa District, is rolling out the late-night red carpet for its hospitality industry folks and friends, with Chef de Cuisine Justin Winter’s creative twists on after-hours snacks. Available every Sunday - Thursday from 10:00PM to last call, La Motta’s is the neighborhood joint for a late-night bash with flavorful bites and brews.
Launching Sunday, February 26th, 2017, guests can expect flavorful options…
Late payment – the hidden challenge facing Europe's businesses
A recent Europe-wide business survey has revealed no improvement in the pressure on European businesses from customers’ late payments, with 55 per cent of businesses across Europe reporting late payments resulting in loss of income, 63 per cent claiming additional pressures on liquidity, and 50 per cent citing late payments as having a direct impact on company growth.
In the Republic of Ireland, 47 per cent of businesses surveyed claimed…
